Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Bringing Lupus Care Closer to Patients: Caterina Brindicci on AstraZeneca’s Next Chapter in Immunology
Shots:  AstraZeneca’s patient-focused immunology vision is reinforced by the EU approval of subcutaneous, self-administered Saphnelo (anifrolimab), offering people with SLE a more convenient option that reduces treatment burden, supports earlier biologic use, and advances the goal of remission beyond symptom control  The new formulation is expected to improve access, uptake, and adherence while easing infusion capacity constraints, with regulatory…
February 4, 2026
Pictor Labs at SITC 2025: Megan Rothney on How ClearStain Is Transforming Molecular Sequencing and Precision Oncology
Shots:  ClearStain debuted at SITC 2025 as a workflow-changing innovation, delivering high-quality virtual H&E images from unstained slides to improve tumor identification, reduce sequencing failures, preserve tissue, and accelerate molecular and precision oncology workflows  By enabling direct visualization and annotation of the exact tissue destined for sequencing, ClearStain helps pathologists and molecular labs maximize tumor purity, minimize impurities,…
January 19, 2026
Inside Anavex’s Alzheimer’s Strategy: Dr. Christopher Missling on Blarcamesine, SIGMAR1, and Precision Medicine 
Shots:   Neurodegenerative care is at a pivotal inflection point, shifting from symptomatic relief to strategies that restore cellular resilience. Blarcamesine (ANAVEX 2-73) advances this upstream approach by activating SIGMAR1 to rebalance autophagy, targeting a core driver of neurodegeneration  Phase IIb/III findings demonstrated a statistically significant slowing of cognitive decline, with the most pronounced benefit seen in patients carrying the…
December 22, 2025
Redefining Respiratory Endpoints: Inside Strados Labs’ Vision for Objective, Real-World Lung Monitoring 
Shots:  Clinical trial sponsors are rapidly moving toward objective, continuous respiratory monitoring, adopting technologies like the RESP Biosensor to improve endpoint sensitivity, safety assessments, and real-world patient insight.  Beyond cough frequency, emerging acoustic biomarkers, such as wheezes, crackles, cough intensity, and cough bout patterns, are redefining how respiratory function and therapeutic impact are measured in modern trials.  PharmaShots welcomes Nick Delmonico,…
December 15, 2025
A New Era for Myeloma Patients: Regeneron’s Karen Rodriguez Lorenc on Lynozyfic’s Rising Global Impact 
Shots:  Lynozyfic is emerging as a standout in heavily pre-treated multiple myeloma. In the pivotal LINKER-MM1 trial, it delivered early, deep, and durable responses, offering renewed hope for patients with limited options. Its response-adapted dosing regimen further reduces treatment burden and enhances convenience  Regeneron is accelerating progress with a broad development strategy, advancing Lynozyfic across multiple therapy lines, combination regimens, precursor conditions, and global markets. The program…
December 8, 2025
Evorpacept’s Momentum in HER2+ Gastric Cancer: A Conversation with Jason Lettmann from ALX Oncology 
Shots:  Evorpacept emerges as the only CD47-blocking therapy with strong clinical activity and a highly manageable safety profile, thanks to its unique inactive Fc design that enables targeted tumor destruction while sparing healthy cells  Updated ASPEN-06 data highlights CD47 overexpression as a powerful predictive biomarker, showing dramatic improvements in ORR, DOR, PFS, and OS for patients with…
December 3, 2025
Inside Sapient’s Multi-Omics Revolution: A Deep Dive with Founder Mo Jain 
Shots:    Sapient’s new partnership with Alamar Biosciences supercharges its multi-omics engine, bringing the ultra-sensitive NULISA™ platform in-house to capture hard-to-measure cytokines and chemokines, unlocking deeper biological insights beyond the reach of mass spectrometry alone  The collaboration with Rancho Biosciences is redefining large-scale data intelligence, enabling Sapient’s DynamiQ™ platform to seamlessly integrate, structure, and analyze massive multi-omics and real-world…
December 1, 2025
Tariffs, Compliance, and the Future of Drug Pricing: A Conversation with Jesse Mendelsohn from Model N 
Shots:    U.S. tariff shifts are forcing pharma manufacturers to accelerate reshoring, reduce duty exposure, and stabilize pricing, fueling renewed investment in onshore final manufacturing, Most Favored Nation pricing strategies, and selective direct-to-consumer pilots to secure tariff relief amid policy volatility  As pricing, reimbursement, market access, and trade regulations evolve, companies are prioritizing late-stage, lower-risk…
November 24, 2025
Inside neffy’s Launch Strategy: A Stimulating Conversation with Richard Lowenthal, CEO & Co-Founder of ARS Pharmaceuticals 
Shots:  Inconsistent access to epinephrine auto-injectors continues to be a major unmet need in the management of anaphylaxis  neffy, an innovative intranasal epinephrine spray, provides a needle-free alternative for the emergency treatment of severe allergic reactions, including anaphylaxis, in adults and children aged four years and older who weigh at least 33 lbs  Richard Lowenthal,…
November 3, 2025
Load more